KyungDong Pharm home
Prescription Medicines

Beporizin tab.10mg

Product Category
Antihistamines
Active Ingredients
Bepotastine besylate
Appearance
A white, round, film-coated tablet.
Reimbursement Code
648103980
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Bepotastine besylate (JP)----10mg
- Additives: Microcrystalline cellulose, titanium oxide, magnesium stearate, croscarmellose sodium, povidone, polyethylene glycol 6000, hypromellose, D-mannitol

2. Effectiveness
Perennial allergic rhinitis, chronic urticaria, pruritus associated with skin disease (eczema, dermatitis, itching, prurigo)

3. Dosage and dosage
Typically, adults are administered orally as bepotastine besylate, 10 mg at a time, twice a day.
Additionally, it increases or decreases appropriately depending on age and symptoms.

4. Precautions for use
1. Do not administer to the following patients
Patients with hypersensitivity to the ingredients of this drug

2. Administer with caution to the following patients:
1) Patients with renal dysfunction
2) Patients with liver dysfunction
3) Elderly patients

3. Adverse reactions
Of the total 1,446 cases in clinical trials, side effects were reported in 137 (9.5%).
1) Mental nervous system: drowsiness, fatigue, headache, heaviness, dizziness
2) Digestive system: dry mouth, dry mouth, glossitis, nausea, vomiting, stomach pain, stomach discomfort, diarrhea
3) Blood system: fluctuations in white blood cell count, hypereosinophilia
4) Liver: Increased AST (GOT), ALT (GPT), r-GTP, LDH, total bilirubin
5) Kidney: urine protein, urine sugar, urine occult blood, urinary urobilinogen
6) Skin: Hypersensitivity reaction with rash and swelling

Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,717 patients over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 1.8% (68/3,717, 80 cases) regardless of causal relationship. Drowsiness 1.26% (47 people/3,717 people, 47 cases), thirst 0.30% (11 people/3,717 people, 11 cases), abdominal discomfort 0.27% (10 people/3,717 people, 10 cases), boredom 0.11% (4 people/3,717 people, 4 cases), facial edema 0.05% (2 people/3,717 people, 2 cases), followed by increased SGOT, increased SGPT, headache, palpitations, facial flushing, and bitter taste at 0.03% (1 person/3,717 people, 1 case). The incidence of adverse drug reactions, which are adverse events in which a causal relationship with this drug cannot be ruled out, was 1.4% (52 people/3,717 people, 62 cases). It has been reported. Drowsiness 1.13% (42 people/3,717 people, 42 cases), thirst 0.24% (9 people/3,717 people, 9 cases), abdominal discomfort 0.11% (4 people/3,717 people, 4 cases), boredom 0.08% (3 people/3,717 people, 3 cases), flushing, increased SGOT, and increased SGPT respectively. It was 0.03% (1 person/3,717 people, 1 case). The occurrence rate of unexpected adverse events that occurred during the domestic post-marketing surveillance period was 0.13% (5 people/3,717 people, 5 cases) regardless of causal relationship, and facial edema was 0.05% (2 people/3,717 people, 2 cases), palpitations, facial flushing, and bitter taste respectively. It was reported as 0.03% (1 person/3,717 people, 1 case). Among these, one case of facial flushing was reported as an adverse drug reaction, which is an adverse event in which a causal relationship with this drug cannot be ruled out. No serious adverse events that occurred during the domestic post-marketing surveillance period were reported.

4. General precautions
1) Because it may cause drowsiness, patients taking this drug should be cautioned about driving a car or operating dangerous machinery.
2) For patients who have been receiving steroid therapy for a long period of time, when reducing the dose of steroids while administering this drug, do so gradually under sufficient management.
3) In patients with renal impairment, the blood concentration of this drug may increase. In addition, because there is a risk that high blood levels may persist, it should be administered cautiously, starting from a low dose (i.e., 5 milligrams per dose), and if abnormalities are observed, appropriate measures such as reduction or withdrawal of medication are required.
4) This agent should be used with caution as it has not been studied in patients with seasonal allergic rhinitis. When administering it, it is advisable to start administration immediately before the season in which the disease occurs and continue until the end of the season in which the disease occurs.
5) If the effect is not confirmed by using this drug, do not administer it for a long period of time.

5. Interaction
As with other antihistamines, do not take it in combination with excessive amounts of alcohol.

6. Administration to pregnant and lactating women
1) The safety of administration during pregnancy has not been established, and it has been found in animal experiments that it transfers to the fetus. Therefore, it is advisable not to administer to pregnant women or women who may be pregnant. However, if administration cannot be avoided, administer only when it is judged that the therapeutic benefits outweigh the risks.
2) Since it has been reported in animal experiments (rats) that it passes into breast milk, it is recommended not to administer to lactating women. However, if this medication is unavoidably administered, breast-feeding should be avoided.

7. Administration to children
Safety in children has not been established.

8. Administration to elderly people
This drug is mainly excreted through the kidneys, and in general, elderly people have reduced physiological functions, so there is a risk that high blood levels will persist, so this drug should be administered with caution when used in elderly people.

9. Effect on clinical test values
This drug inhibits the intradermal reaction to allergens and may interfere with the identification of allergens, so it is advisable not to administer this drug before conducting an intradermal reaction test.

10. Application precautions
When teaching medication, instruct students to take medications in PTP packaging by taking them out of the PTP sheet.
(There have been reports of cases where PTP sheets were swallowed incorrectly and the hard, sharp parts irritated the esophageal mucosa, causing perforation and serious complications such as mediastinitis.)

11. Storage and handling precautions
1) Store out of reach of children.
2) Store below 30℃, avoiding moisture.

12. Pharmaceutical equivalence test information
A. The test drug Bepotastine besylate 10 mg tablet (KyungDong Pharm Co., Ltd.) and the reference drug Tarion tablet 10 mg (Dong-A ST Co., Ltd.) were administered orally once to healthy adults in a 2 The 90% confidence interval was within log 0.8 to log 1.25, proving biological equivalence.
※ Table: Refer to attached document

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 300 tablets/bottle

7. Period of use
36 months from date of manufacture